Continuous Warfarin (Antithrombin therapy) administration versus Heparin bridge therapy in post colon polypectomy hemorrhage

Continuous Warfarin (Antithrombin therapy) administration versus Heparin bridge therapy in post colon polypectomy hemorrhage - WHICH study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023720

Enrollment

316

Registered

2016-09-01

Start date

2016-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colon polyp

Interventions

a heparin bridging therapy group Patients stopped taking warfarin at the 4 days before the procedure.Administration of heparin was started at the day when interruption of warfarin. The prothrombin ti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with colorectal polyp becoming the indication of polypectomy or EMR. 2)Patients taking warfarin for more than 2 weeks before the procedure. 3)Patients is more than 20 years old. 4)obtaining the consent of the patient

Exclusion criteria

Exclusion criteria: 1)Patients have already registered 2)Patients with inflammatory bowel disease, familial adenomatous polyposis, or Peutz-Jeghers syndrome 3)We cannot observe the progress of the patients 4)patients with bleeding within 6 weeks before the procedure 5)Patients who undergo hemodialys 6)Plt is less than 50000/mm3 7)Patients with the abnormality in blood coagulation ability 8)Woman who is during pregnancy 9)Patients are nursing mothers 10)Patients have an allergy to warfarin or heparin. 11)The attending physician has determined that it is difficult to entry

Design outcomes

Primary

Measure	Time frame
the incidence of post polypectomy and EMR bleeding	—

Secondary

Measure	Time frame
1 cumulative post polypectomy and EMR bleeding rate 2 the rate of overt bleeding which dose not satisfy the definiton of post polypectomy and EMR bleeding 3 the rate of immediate bleeding requiring endoscopic intervention 4 immediate bleeding requiring angiography or surgery or blood transfusion 5 general incidence of bleeding 6 risk factors for post polypectomy and EMR bleeding 7 days of hospital stay 8 the incidence of thromboembolism 9 PT-INR at 28 days after polypectomy and EMR 10 the incidence of serious adverse event	—

Measure

Time frame

1 cumulative post polypectomy and EMR bleeding rate 2 the rate of overt bleeding which dose not satisfy the definiton of post polypectomy and EMR bleeding 3 the rate of immediate bleeding requiring endoscopic intervention 4 immediate bleeding requiring angiography or surgery or blood transfusion 5 general incidence of bleeding 6 risk factors for post polypectomy and EMR bleeding 7 days of hospital stay 8 the incidence of thromboembolism 9 PT-INR at 28 days after polypectomy and EMR 10 the incidence of serious adverse event

—

Countries

Japan

Contacts

Public ContactYasuaki Nagami

Osaka City University Graduate School of Medicine Department of Gastroenterology

yasuaki-75@med.osaka-cu.ac.jp06-6645-3811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026